Stuart Pocock

Summary

Affiliation: London School of Hygiene and Tropical Medicine
Country: UK

Publications

  1. ncbi Issues in the reporting of epidemiological studies: a survey of recent practice
    Stuart J Pocock
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 329:883. 2004
  2. ncbi The simplest statistical test: how to check for a difference between treatments
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 332:1256-8. 2006
  3. ncbi How to interpret figures in reports of clinical trials
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 336:1166-9. 2008
  4. ncbi The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
    Stuart J Pocock
    Department of Medical Statistics, London School of Hygiene and Tropical Medicine, UK
    Eur Heart J 33:176-82. 2012
  5. ncbi Categorisation of continuous risk factors in epidemiological publications: a survey of current practice
    Elizabeth L Turner
    Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
    Epidemiol Perspect Innov 7:9. 2010
  6. ncbi Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
    Michel Komajda
    Université Pierre et Marie Curie Paris 6 Assistance Publique Hôpitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Cardiovasc Diabetol 7:10. 2008
  7. ncbi Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK
    Eur Heart J 29:2641-50. 2008
  8. ncbi The data monitoring experience in the MOXCON trial
    Stuart Pocock
    Medical Statistics Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Eur Heart J 25:1974-8. 2004
  9. ncbi Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Circulation 121:43-51. 2010
  10. ncbi A major trial needs three statisticians: why, how and who?
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Stat Med 23:1535-9. 2004

Detail Information

Publications58

  1. ncbi Issues in the reporting of epidemiological studies: a survey of recent practice
    Stuart J Pocock
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 329:883. 2004
    ..To review current practice in the analysis and reporting of epidemiological research and to identify limitations...
  2. ncbi The simplest statistical test: how to check for a difference between treatments
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 332:1256-8. 2006
  3. ncbi How to interpret figures in reports of clinical trials
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 336:1166-9. 2008
  4. ncbi The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
    Stuart J Pocock
    Department of Medical Statistics, London School of Hygiene and Tropical Medicine, UK
    Eur Heart J 33:176-82. 2012
    ..The win ratio is a new method for reporting composite endpoints, which is easy to use and gives appropriate priority to the more clinically important event, e.g. mortality. We encourage its use in future trial reports...
  5. ncbi Categorisation of continuous risk factors in epidemiological publications: a survey of current practice
    Elizabeth L Turner
    Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
    Epidemiol Perspect Innov 7:9. 2010
    ..Using the survey results we provide illustrative examples and, combined with ideas from the broader literature and from experience, we offer guidelines for good practice...
  6. ncbi Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
    Michel Komajda
    Université Pierre et Marie Curie Paris 6 Assistance Publique Hôpitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Cardiovasc Diabetol 7:10. 2008
    ..We therefore used ambulatory BP to quantify BP lowering at 6-12 months with rosiglitazone used in combination with metformin or sulfonylureas compared to metformin and sulfonylureas in people with type 2 diabetes...
  7. ncbi Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK
    Eur Heart J 29:2641-50. 2008
    ....
  8. ncbi The data monitoring experience in the MOXCON trial
    Stuart Pocock
    Medical Statistics Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Eur Heart J 25:1974-8. 2004
    ....
  9. ncbi Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Circulation 121:43-51. 2010
    ....
  10. ncbi A major trial needs three statisticians: why, how and who?
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Stat Med 23:1535-9. 2004
    ....
  11. ncbi A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials
    S J Pocock
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 323:75-81. 2001
    ..To create a risk score for death from cardiovascular disease that can be easily used...
  12. ncbi The pros and cons of noninferiority trials
    Stuart J Pocock
    Medical Statistics Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT UK
    Fundam Clin Pharmacol 17:483-90. 2003
    ....
  13. ncbi Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
    Stat Med 21:2917-30. 2002
    ....
  14. ncbi Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK
    Lancet 359:1686-9. 2002
    ....
  15. ncbi Current controversies in data monitoring for clinical trials
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK
    Clin Trials 3:513-21. 2006
    ..The examples serve to illustrate that the practicalities of DMC decision-making require wise judgements based on a totality of evidence, making any statistical boundary just an objective guideline rather than a definitive stopping rule...
  16. ncbi Predictors of mortality and morbidity in patients with chronic heart failure
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Eur Heart J 27:65-75. 2006
    ..We aimed to develop prognostic models for patients with chronic heart failure (CHF)...
  17. ncbi The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Stuart Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
    Am Heart J 149:939-43. 2005
    ....
  18. ncbi Data monitoring in randomized controlled trials: surveys of recent practice and policies
    Felicity Clemens
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Clin Trials 2:22-33. 2005
    ..Three interlinked surveys were carried out as part of the DAMOCLES project to explore recent and current DMC practice and policy...
  19. ncbi Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age
    Joseph Kim
    Medical Statistics Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Int J Epidemiol 35:731-8. 2006
    ....
  20. ncbi Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
    Neil R Poulter
    Imperial College London, London, UK
    Lancet 366:907-13. 2005
    ..86 and 0.77, respectively). Our aim was to assess to what extent these differences were due to significant differences in blood pressures and in other variables noted after randomisation...
  21. ncbi Coping with missing data in clinical trials: a model-based approach applied to asthma trials
    James Carpenter
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Stat Med 21:1043-66. 2002
    ..We further propose the use of a time transformation to linearize an asymptotic pattern of repeated measures over time and therefore simplify the modelling. All these ideas are illustrated using data from a five-arm asthma clinical trial...
  22. ncbi Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3)
    Joseph Kim
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    J Am Coll Cardiol 45:221-8. 2005
    ..We sought to compare the effects of an early interventional strategy (IS) versus a conservative strategy (CS) on health-related quality of life (HRQOL) in patients with non-ST-segment elevation acute coronary syndromes (ACS)...
  23. ncbi The risk of fractures associated with thiazolidinediones: a self-controlled case-series study
    Ian J Douglas
    Non Communicable Disease Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS Med 6:e1000154. 2009
    ..Our objective was to further investigate the risk of fracture associated with thiazolidinedione use...
  24. ncbi Adjusting treatment comparisons to account for non-randomized interventions: an example from an angina trial
    Ian R White
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Stat Med 22:781-93. 2003
    ..Such methods may be of interest to many pragmatic randomized trials in which the effects of the initial randomized treatments and the effects of the overall treatment strategies as implemented are both of interest...
  25. ncbi Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
    Peter J Barnes
    Imperial College, London, UK
    Pulm Pharmacol Ther 23:165-71. 2010
    ..This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease)...
  26. ncbi Impact of missing data due to selective dropouts in cohort studies and clinical trials
    Giota Touloumi
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK
    Epidemiology 13:347-55. 2002
    ..The objective of this paper is to evaluate the impact of selective dropouts attributable to death or disease progression on the estimates of marker change among different groups...
  27. ncbi Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients
    Tim C Clayton
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 331:869. 2005
    ..CONCLUSION: This risk score is an objective aid in deciding on further management of patients with stable angina with the aim of reducing serious outcome events. The score can also be used in planning future trials...
  28. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine ISPM, University of Bern, Finkenhubelweg 11, CH 3012 Bern, Switzerland
    Prev Med 45:247-51. 2007
    ..We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies...
  29. ncbi Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 50:40-7. 2007
    ..The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients...
  30. ncbi Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, United Kingdom
    N Engl J Med 357:28-38. 2007
    ..A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes...
  31. ncbi Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
    Nathaniel M Hawkins
    Stobhill Hospital, Glasgow, UK
    Eur J Heart Fail 9:510-7. 2007
    ..The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood...
  32. ncbi An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a 2x2x2x2x2x2 factorial design (IMPACT)
    Christian C Apfel
    Department of Anesthesiology, University of Wuerzburg, Wuerzburg, Germany
    Control Clin Trials 24:736-51. 2003
    ..To the best of our knowledge this is the first randomized controlled trial of a six-way factorial design that may serve as an example for numerous other medical specialties...
  33. ncbi Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement
    Gilda Piaggio
    Statistics and Informatics Services Group, Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
    JAMA 295:1152-60. 2006
    ..The intent is to improve reporting of noninferiority and equivalence trials, enabling readers to assess the validity of their results and conclusions...
  34. ncbi Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy
    Robert A Henderson
    Department of Cardiology, Nottingham City Hospital, Nottingham, United Kingdom
    J Am Coll Cardiol 42:1161-70. 2003
    ..This study was designed to compare the long-term consequences of percutaneous transluminal coronary angioplasty (PTCA) and continued medical treatment...
  35. ncbi Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial
    Alexandre Mebazaa
    Department of Anesthesiology, Université Paris Diderot and Hospital Lariboisière AP HP, Paris, France
    JAMA 297:1883-91. 2007
    ..Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival...
  36. ncbi [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]
    Erik von Elm
    Institute of Social and Preventive Medicine ISPM, University of Bern, Berna, Switzerland
    Gac Sanit 22:144-50. 2008
    ..We hope that the STROBE statement will contribute to improving the quality of reporting of observational studies...
  37. ncbi More on subgroup analyses in clinical trials
    Stuart J Pocock
    N Engl J Med 358:2076; author reply 2076-7. 2008
  38. ncbi Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials
    Ian R White
    MRC Biostatistics Unit, Institute of Public Health, Robinson Way, Cambridge CB2 2SR, U K
    Stat Med 24:3805-21. 2005
    ....
  39. ncbi Bivalirudin during primary PCI in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 358:2218-30. 2008
    ..The safety and efficacy of bivalirudin in high-risk patients are unknown...
  40. ncbi [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]
    Erik von Elm
    Institute of Social and Preventive Medicine ISPM, University of Bern, Berna, Suiza
    Rev Esp Salud Publica 82:251-9. 2008
    ..We hope that the STROBE statement will contribute to improving the quality of reporting of observational studies...
  41. ncbi When (not) to stop a clinical trial for benefit
    Stuart J Pocock
    JAMA 294:2228-30. 2005
  42. ncbi Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis
    Eugenia Nikolsky
    Cardiovascular Research Foundation and the Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA
    J Am Coll Cardiol 44:1200-9. 2004
    ..79). CONCLUSIONS: In the setting of Dx angiography, the risk of access-site-related complications was similar for ACD compared with mechanical compression. In the setting of PCI, the rate of complications appeared higher with VasoSeal...
  43. ncbi Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Lancet 364:849-57. 2004
    ..We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris...
  44. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland
    J Clin Epidemiol 61:344-9. 2008
    ..We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies...
  45. ncbi Safety of drug-eluting stents: demystifying network meta-analysis
    Stuart J Pocock
    Lancet 370:2099-100. 2007
  46. ncbi Bivalirudin for patients with acute coronary syndromes
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 355:2203-16. 2006
    ..We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients...
  47. ncbi Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    JAMA 297:591-602. 2007
    ..The preferred approach is undetermined...
  48. ncbi Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Satish Kenchaiah
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 116:627-36. 2007
    ..However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality...
  49. ncbi Costs of an early intervention versus a conservative strategy in acute coronary syndrome
    David M Epstein
    Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK
    Int J Cardiol 127:240-6. 2008
    ..This paper uses data from the RITA-3 trial to compare the health service costs of the two strategies...
  50. ncbi Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration
    Jan P Vandenbroucke
    Leiden University Medical Center, Leiden, The Netherlands
    Ann Intern Med 147:W163-94. 2007
    ..Examples of useful flow diagrams are also included. The STROBE Statement, this document, and the associated Web site (www.strobe-statement.org) should be helpful resources to improve reporting of observational research...
  51. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
    Ann Intern Med 147:573-7. 2007
    ..annals.org and on the Web sites of PLoS Medicine and Epidemiology. We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies...
  52. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS Med 4:e296. 2007
    ..We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies...
  53. ncbi Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration
    Jan P Vandenbroucke
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    PLoS Med 4:e297. 2007
    ..Examples of useful flow diagrams are also included. The STROBE Statement, this document, and the associated Web site (http://www.strobe-statement.org/) should be helpful resources to improve reporting of observational research...
  54. ncbi Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 356:998-1008. 2007
    ..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data...
  55. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
    Bull World Health Organ 85:867-72. 2007
    ..We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies...
  56. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    Epidemiology 18:800-4. 2007
    ..We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies...
  57. ncbi Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration
    Jan P Vandenbroucke
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    Epidemiology 18:805-35. 2007
    ..Examples of useful flow diagrams are also included. The STROBE Statement, this document, and the associated web site (http://www.strobe-statement.org) should be helpful resources to improve reporting of observational research...
  58. ncbi The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    Erik von Elm
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    Lancet 370:1453-7. 2007
    ..We hope that the STROBE statement will contribute to improving the quality of reporting of observational studies..